 |
0 Diseases |  |
6 Trials |
|
6 Trials |  |
48 News |  |
| 12» |
- || favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov) - Feb 28, 2025
P1/2, N=174, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Oct 2028 --> Jan 2026 | Trial primary completion date: Oct 2028 --> Jan 2026
- Keytruda (pembrolizumab) / Merck (MSD)
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC). (Level 1, West Hall; Poster Bd #: G19) - Jan 7, 2025 - Abstract #ASCOGU2025ASCO_GU_469;
P1/2
Trial completion date: Oct 2028 --> Jan 2026 | Trial primary completion date: Oct 2028 --> Jan 2026 We present results from arms containing only immunotherapy regimens: arm B1 (quavonlimab [qmab; anti
- || favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov) - Dec 26, 2024
P1/2, N=174, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
We present results from arms containing only immunotherapy regimens: arm B1 (quavonlimab [qmab; anti Recruiting --> Active, not recruiting
- favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study. (Level 1, West Hall; Poster Bd #: K8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_933;
P3
Clinical Trial Registration Number: NCT05064059. The abstract will be released to the public on January 25, 2025 at 3:00 PM UTC
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
UPDATED ANALYSIS OF A PHASE 1/2 STUDY EVALUATING PEMBROLIZUMAB (PEMBRO) PLUS THE ANTI (Gro) - Oct 31, 2024 - Abstract #ISHL2024ISHL_205;
P1/2, P3
The abstract will be released to the public on January 25, 2025 at 3:00 PM UTC With additional follow-up, pembro plus favezelimab continued to demonstrate manageable safety and sustained antitumor activity in pts with heavily pretreated anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
UPDATED ANALYSIS OF A PHASE 1/2 STUDY EVALUATING PEMBROLIZUMAB (PEMBRO) PLUS THE ANTI (Gro) - Oct 31, 2024 - Abstract #ISHL2024ISHL_204;
P1/2
With additional follow-up, pembro plus favezelimab continued to demonstrate manageable safety and sustained antitumor activity in pts with heavily pretreated anti With additional follow-up, pembro+favezelimab continued to demonstrate manageable safety and sustained antitumor activity in pts with anti
- || favezelimab (MK-4280) / Merck (MSD), relatlimab (BMS-986016) / BMS, fianlimab (REGN3767) / Regeneron
Review, Journal: Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements. (Pubmed Central) - Oct 19, 2024
Currently, with the approval of relatlimab, a LAG-3 blocking antibody, a third player, has been used in the fight against cancer...However, the complex biology of LAG-3 may hinder its full development as a therapeutic alternative. In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment.
- || favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov) - Sep 19, 2024
P1/2, N=174, Recruiting, Sponsor: Merck Sharp & Dohme LLC
In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment. Trial completion date: Apr 2028 --> Oct 2028 | Trial primary completion date: Apr 2028 --> Oct 2028
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
PEMBROLIZUMAB PLUS THE ANTI (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1944;
P1/2
Trial completion date: Apr 2028 --> Oct 2028 | Trial primary completion date: Apr 2028 --> Oct 2028 In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andsustained antitumor activity in pts with anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
PEMBROLIZUMAB PLUS THE ANTI (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1943;
P1/2, P3
In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andsustained antitumor activity in pts with anti In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andantitumor activity in pts with heavily pretreated anti
- || favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov) - Apr 25, 2024
P1/2, N=174, Recruiting, Sponsor: Merck Sharp & Dohme LLC
In this updated analysis, pembrolizumab plus favezelimab continued to demonstrate manageable safety andantitumor activity in pts with heavily pretreated anti Trial completion date: Oct 2027 --> Apr 2028 | Trial primary completion date: Oct 2027 --> Apr 2028
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti (Hall A; Poster Bd #: 39) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2391;
P1/2, P3
Trial completion date: Oct 2027 --> Apr 2028 | Trial primary completion date: Oct 2027 --> Apr 2028 After additional follow-up, favezelimab + pembrolizumab continued to demonstrate manageable safety and antitumor activity in pts with heavily pretreated anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
A phase 1/2 study of favezelimab in combination with pembrolizumab for anti (Hall A; Poster Bd #: 38) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2390;
P1/2
After additional follow-up, favezelimab + pembrolizumab continued to demonstrate manageable safety and antitumor activity in pts with heavily pretreated anti With additional follow-up, favezelimab plus pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in pts with anti
- ||| Trial completion, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Mar 27, 2024
P1, N=482, Completed, Sponsor: Merck Sharp & Dohme LLC
With additional follow-up, favezelimab plus pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in pts with anti Active, not recruiting --> Completed
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD), vibostolimab (MK-7684) / Merck (MSD)
Screen D: Trials in progress Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (pembro) and favezelimab or vibostolimab for patients with bacillus Calmette-Gu (EGPT) - Jan 15, 2024 - Abstract #EAU2024EAU_2650;
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD), vibostolimab (MK-7684) / Merck (MSD)
Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Gu (Level 1, West Hall; Poster Bd # M19) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_674;
P2
Enrollment is ongoing in Asia, Australia, Europe, North America, and South America. Clinical trial information: NCT02625961.
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5881;
P1/2, P3
Clinical trial information: NCT02625961. After additional follow-up, the combination of favezelimab + pembrolizumab continued to demonstrate manageable safety and antitumor activity in patients with heavily pretreated anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Favezelimab (anti (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2145;
P1/2
Analyses are underway to identify biomarkers predictive of response to the combination of favezelimab and pembrolizumab. The safety profile was manageable and consistent with that observed in other cohorts in the study.
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Favezelimab in Combination with Pembrolizumab in Patients with Anti (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2112;
P1/2
The safety profile was manageable and consistent with that observed in other cohorts in the study. With additional follow-up, the combination of favezelimab and pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in patients with anti
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ? 1 cutoff (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_379;
P1
With additional follow-up, the combination of favezelimab and pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in patients with anti 1 Recent results from MK4280
- || favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov) - Sep 13, 2023
P1/2, N=174, Recruiting, Sponsor: Merck Sharp & Dohme LLC
1 Recent results from MK4280 Trial completion date: Feb 2028 --> Oct 2027 | Trial primary completion date: Feb 2028 --> Oct 2027
- || favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov) - Aug 28, 2023
P1/2, N=174, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Feb 2028 --> Oct 2027 | Trial primary completion date: Feb 2028 --> Oct 2027 Trial completion date: Oct 2027 --> Feb 2028 | Trial primary completion date: Oct 2027 --> Feb 2028
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1 (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1336;
Trial completion date: Oct 2027 --> Feb 2028 | Trial primary completion date: Oct 2027 --> Feb 2028 In this post hoc analysis, the combination of favezelimab + pembrolizumab was associated with a higher ORR and deeper responses than pembrolizumab monotherapy in patients with PD-1
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1328;
P1/2
In this post hoc analysis, the combination of favezelimab + pembrolizumab was associated with a higher ORR and deeper responses than pembrolizumab monotherapy in patients with PD-1 The combination of favezelimab plus pembrolizumab continued to demonstrate antitumor activity and manageable safety in pts with R/R cHL whose disease progressed following anti
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1325;
P1/2
The combination of favezelimab plus pembrolizumab continued to demonstrate antitumor activity and manageable safety in pts with R/R cHL whose disease progressed following anti Favezelimab + pembrolizumab continued to demonstrate sustained antitumor activity and acceptable safety in anti
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
An open-label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti-PD-1 treatment () - May 4, 2023 - Abstract #ICML2023ICML_544;
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Favezelimab plus pembrolizumab in anti (Room B) - May 4, 2023 - Abstract #ICML2023ICML_66;
- || Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - May 1, 2023
P1, N=576, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Favezelimab + pembrolizumab continued to demonstrate sustained antitumor activity and acceptable safety in anti Trial completion date: Oct 2024 --> Mar 2024 | Trial primary completion date: Oct 2024 --> Mar 2024
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD), vibostolimab (MK-7684) / Merck (MSD)
Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Gu (On Demand | Level 1, West Hall; Poster Board No. P14) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_685;
P2
Efficacy will be evaluated in all pts who received ?1 dose of study treatment and have a baseline evaluation consisting of pre-enrollment cystoscopy, TURBT/biopsy, urine cytology, and baseline CT urography imaging. Clinical trial information: NCT02625961.
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD), vibostolimab (MK-7684) / Merck (MSD)
Pembrolizumab with favezelimab or vibostolimab for patients with high-risk (HR) bacillus Calmette-Gu (Blue Area, Room 1) - Dec 27, 2022 - Abstract #EAU2023EAU_1383;
P2
- favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer. (Available On Demand; Poster Board No. G16) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_215;
P1
The combination therapy showed antitumor activity in line with other checkpoint inhibitors in advanced gastric cancer though higher antitumor activity was seen in PDL1 CPS≥ 1 tumors, particularly at higher dose. Clinical trial information: NCT02720068.
- || favezelimab (MK-4280) / Merck (MSD)
#ASH22 #lymsm #Hodgkin #favezelimab (Twitter) - Dec 10, 2022
- |||| favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
P2 data: Favezelimab + Pembro R-R cHL. • Phase 2. PD1 failed, about half last line, about half not. • ORR 29% but most did have a reduction in volume. • med PFS 10.7mo • did keep some stable • LFT abN & IRRs Some activity but appears modest. Not clear what the lag3 adding. #ASH22 (Twitter) - Dec 10, 2022
- ||||| favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Clinical: CKPi refractory Hodgkin is unmet need. Favezelimab (LAG-3i) + Pembro has actively in about third of patients #ASH22 #lymsm (Twitter) - Dec 10, 2022
- || favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
P1 data, Journal: A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. (Pubmed Central) - Dec 10, 2022
Favezelimab with or without pembrolizumab had a manageable safety profile, with no treatment-related deaths. Promising antitumor activity was observed with combination therapy, particularly in participants with PD-L1 CPS ≥1 tumors.
- ||| favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
#Favezelimab added to Pembro in RR cHL #lymsm showing ORR of 29%. More options needed in post PD1i progression in cHL #ASH22 https://t.co/HWzB79Z2Lj (Twitter) - Dec 8, 2022
- ||| favezelimab (MK-4280) / Merck (MSD), favezelimab/pembrolizumab (MK-4280A) / Merck (MSD)
Important: A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable #colorectal cancer. Just published in @ESMO_Open by @myESMO https://t.co/EbLQiGy4do (Twitter) - Dec 8, 2022
- ||||| Clinical, P2 data: Invited abstract 635 @DrRoyHerbstYale @YaleMed reviews updates on KEYNOTE-495 randomized phase 2 in #NSCLC with pembro+lenvatinib or quavonlimab or favezelimab. Median PFS and OS were longer in T cell inf GEP nonlow TMB high subgroup @sitcancer #SITC22 (Twitter) - Nov 10, 2022
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4290;
P1/2
After additional follow-up, favezelimab plus pembrolizumab combination therapy continued to demonstrate sustained antitumor activity and acceptable safety in anti–PD-1–naive patients with R/R cHL. Further studies comparing the activity of this combination to that of single-agent pembrolizumab would be of clinical benefit.
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment (ENMCC - 278-282) - Nov 4, 2022 - Abstract #ASH2022ASH_1735;
P1/2
After additional follow-up, favezelimab plus pembrolizumab combination therapy continued to demonstrate sustained antitumor activity and acceptable safety in pts with R/R cHL whose disease progressed following anti–PD-1 therapy. A phase 3 study is planned to further investigate the promising results found in this patient population.
- ||||| favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Clinical: Pembro (PD1i) + favezelimab (LAG3i) in R/R Hodgkin with prior anti-PD1i. ORR 29% & CRR 9%. Modest - although 89% had ⬇️ in target lesions. Median DOR 19.4mo. Randomised study ongoing. #ASH22 Timmerman et al - https://t.co/3h4kgYlMAq (Twitter) - Nov 3, 2022
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Great Hall) - Oct 27, 2022 - Abstract #ISHL2022ISHL_62;
P1/2
Favezelimab 800 mg + pembro 200 mg Q3W demonstrated acceptable safety and effective antitumor activity in anti–PD-1–naive pts with R/R cHL. Comparative studies on its activity to that of single-agent pembro would be of clinical benefit.
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment (Great Hall) - Oct 27, 2022 - Abstract #ISHL2022ISHL_59;
P1/2
Favezelimab 800 mg + pembrolizumab 200 mg Q3W demonstrated acceptable safety and effective antitumor activity in pts with R/R cHL and PD following anti–PD-1 therapy. This combination shows potential to reinduce a response in this pt population.
- ||| favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Dr Timmerman: favezelimab (anti-LAG3) & pembro in CPI-refract cHL - ORR 30% (but 5 unknown), CRR 9% - Expected immune related reactions A signal of activity in this pt group but unclear where its role will be in the pathway. Ph3 vs Ix choice starting. #ISHL12. (Twitter) - Oct 23, 2022
- || favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov) - Aug 22, 2022
P1/2, N=174, Recruiting, Sponsor: Merck Sharp & Dohme LLC
This combination shows potential to reinduce a response in this pt population. Trial completion date: Dec 2026 --> Oct 2027 | Trial primary completion date: Dec 2026 --> Oct 2027
- Keytruda (pembrolizumab) / Merck (MSD)
KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Hall B2) - Aug 4, 2022 - Abstract #SITC2022SITC_109;
P2
Although response in the pembrolizumab+favezelimab arm did not reach the efficacy bar, there was a trend toward improved ORR in the Tcell inf GEP non-low TMB high subgroup versus the other 3 biomarker-defined subgroups; median PFS and OS were also numerically longer in the Tcell inf GEP non-low TMB high subgroup compared with the other 3 biomarker-defined subgroups. Prospective assessment of dual biomarkers, as performed in this study, may help identify patients with NSCLC most likely to respond to pembrolizumab-based combination therapies.
- || favezelimab (MK-4280) / Merck (MSD)
What's the secret sauce $BMY has that $IMMP lacks? Note $MRK has Lag3 data (favezelimab, albeit in Hodgkin's) at #ASCO22 (Twitter) - Jun 3, 2022
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY () - May 13, 2022 - Abstract #EHA2022EHA_1462;
P1/2
- favezelimab (MK-4280) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY () - May 13, 2022 - Abstract #EHA2022EHA_1461;
P1/2
- Keytruda (pembrolizumab) / Merck (MSD)
Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_198;
P2
Targeting a different pathway such as CTLA-4, LAG-3, TIGIT, or ILT4 using a second checkpoint inhibitor may improve the efficacy of PD-1 inhibition. This ongoing, open-label, multicenter, multiarm, randomized, phase 2 trial (NCT04895722) will enroll patients in 2 cohorts, A and B. This study will evaluate efficacy and safety of coformulated pembrolizumab and anti–CTLA-4 quavonlimab compared with pembrolizumab monotherapy in chemotherapy-refractory stage IV dMMR/MSI-H CRC in cohort A. In cohort B, the study will evaluate the efficacy and safety of 4 pembrolizumab-based combinations (coformulated pembrolizumab with either quavonlimab, anti–LAG-3 favezelimab, or anti-TIGIT vibostolimab; anti-ILT4 antibody MK-4830 given sequentially with pembrolizumab) compared with pembrolizumab monotherapy in previously untreated stage IV dMMR/MSI-H CRC.